Bristol Myers Squibb’s subcutaneous nivolumab shows promise in Phase 3 RCC trial

Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize treatment for patients with advanced or metastatic ... Read More